{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:40:16Z","timestamp":1788871216958,"version":"build-2803163510"},"reference-count":52,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2013,7,17]],"date-time":"2013-07-17T00:00:00Z","timestamp":1374019200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Roche Pharma"},{"DOI":"10.13039\/100010154","name":"FISEVI","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010154","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2014,3]]},"abstract":"Summary<\/jats:title>\n \n Studies on the association between the peginterferon\u2010\u03b1 and ribavirin levels and sustained virological response (\n SVR<\/jats:styled-content>\n ) have shown yielded conflicting results, but most of them were performed before the influence of\n IL<\/jats:styled-content>\n 28\n B<\/jats:styled-content>\n polymorphisms was known. Our aim was to assess the effects of peginterferon\u2010\u03b1 2a and ribavirin plasma levels on viral kinetics and\n SVR<\/jats:styled-content>\n in hepatitis C virus genotype 1\n HCV<\/jats:styled-content>\n \u20101\/\n HIV<\/jats:styled-content>\n \u2010co\u2010infected patients according to\n IL<\/jats:styled-content>\n 28\n B<\/jats:styled-content>\n genotype. This was a cohort study of\n HCV<\/jats:styled-content>\n \u20101\/\n HIV<\/jats:styled-content>\n \u2010co\u2010infected patients who were\n HCV<\/jats:styled-content>\n \u2010treatment na\u00efve and for whom the efficacy of peginterferon\u2010\u03b1 2a plus ribavirin was evaluated by per\u2010protocol analysis. The peginterferon\u2010\u03b1 2a and ribavirin levels were measured by\n ELISA<\/jats:styled-content>\n and\n HPLC<\/jats:styled-content>\n \u2010\n UV<\/jats:styled-content>\n , respectively. The relationships among host and viral factors, the trough drugs levels and virological responses were analysed by multivariate regression analyses. A total of 131 Caucasian patients were included (cirrhosis:38.9%). Overall,\n SVR<\/jats:styled-content>\n rate was 39.6%. In patients with\n CC IL<\/jats:styled-content>\n 28B genotype,\n SVR<\/jats:styled-content>\n was related neither to peginterferon\u2010\u03b1 2a nor to ribavirin plasma levels, while higher levels of both drugs were the only variables independently associated with\n SVR<\/jats:styled-content>\n in individuals with\n CT<\/jats:styled-content>\n \/\n TT IL<\/jats:styled-content>\n 28\n B<\/jats:styled-content>\n genotypes (\n OR<\/jats:styled-content>\n , 5.02;\n CI<\/jats:styled-content>\n 95<\/jats:sub>\n , 1.45\u201317.1;\n P<\/jats:italic>\n \u00a0=\u00a00.001 and 4.0;\n CI<\/jats:styled-content>\n 95<\/jats:sub>\n , 1.08\u201314.7;\n P<\/jats:italic>\n \u00a0=\u00a00.038, respectively). Moreover, faster viral declines were observed in\n CT<\/jats:styled-content>\n \/\n TT<\/jats:styled-content>\n patients when peg\n IFN<\/jats:styled-content>\n \u2010\u03b1 2a and ribavirin plasma levels were greater than 3400\u00a0pg\/mL and 1.6\u00a0\u03bcg\/mL, respectively. In contrast to the results for\n CC<\/jats:styled-content>\n patients, the results in patients carrying the unfavourable\n CT<\/jats:styled-content>\n \/\n TT IL<\/jats:styled-content>\n 28\n B<\/jats:styled-content>\n genotypes showed that plasma levels of both drugs have significant effects on viral kinetics and\n SVR<\/jats:styled-content>\n .\n <\/jats:p>","DOI":"10.1111\/jvh.12128","type":"journal-article","created":{"date-parts":[[2013,7,17]],"date-time":"2013-07-17T05:21:05Z","timestamp":1374038465000},"page":"178-188","source":"Crossref","is-referenced-by-count":6,"title":["Impact of the peginterferon\u2010\u03b1 2a and ribavirin plasma levels on viral kinetics and sustained virological response in genotype 1\n HCV<\/scp>\n \/\n HIV<\/scp>\n \u2010co\u2010infected patients with the unfavourable non\u2010\n CC IL<\/scp>\n 28B genotypes"],"prefix":"10.1111","volume":"21","author":[{"given":"A.","family":"Torres\u2010Cornejo","sequence":"first","affiliation":[{"name":"Enfermedades Infecciosas Microbiolog\u00eda y Medicina Preventiva Hospital Universitario Virgen del Roc\u00edo. Instituto de Biomedicina de Sevilla (IBiS) Hospital Universitario Virgen del Roc\u00edo\/CSIC\/Universidad de Sevilla Sevilla Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Ruiz\u2010Valderas","sequence":"additional","affiliation":[{"name":"Enfermedades Infecciosas Microbiolog\u00eda y Medicina Preventiva Hospital Universitario Virgen del Roc\u00edo. Instituto de Biomedicina de Sevilla (IBiS) Hospital Universitario Virgen del Roc\u00edo\/CSIC\/Universidad de Sevilla Sevilla Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Jimenez\u2010Jimenez","sequence":"additional","affiliation":[{"name":"Bioqu\u00edmica Cl\u00ednica Hospital Universitario Virgen del Roc\u00edo Sevilla Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Abad\u2010Molina","sequence":"additional","affiliation":[{"name":"Inmunolog\u00eda Hospital Universitario Virgen del Roc\u00edo. Instituto de Biomedicina de Sevilla (IBiS) Hospital Universitario Virgen del Roc\u00edo\/CSIC\/Universidad de Sevilla Sevilla Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gutierrez\u2010Valencia","sequence":"additional","affiliation":[{"name":"Enfermedades Infecciosas Microbiolog\u00eda y Medicina Preventiva Hospital Universitario Virgen del Roc\u00edo. Instituto de Biomedicina de Sevilla (IBiS) Hospital Universitario Virgen del Roc\u00edo\/CSIC\/Universidad de Sevilla Sevilla Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Viciana","sequence":"additional","affiliation":[{"name":"Enfermedades Infecciosas Microbiolog\u00eda y Medicina Preventiva Hospital Universitario Virgen del Roc\u00edo. Instituto de Biomedicina de Sevilla (IBiS) Hospital Universitario Virgen del Roc\u00edo\/CSIC\/Universidad de Sevilla Sevilla Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. F.","family":"Lopez\u2010Cortes","sequence":"additional","affiliation":[{"name":"Enfermedades Infecciosas Microbiolog\u00eda y Medicina Preventiva Hospital Universitario Virgen del Roc\u00edo. Instituto de Biomedicina de Sevilla (IBiS) Hospital Universitario Virgen del Roc\u00edo\/CSIC\/Universidad de Sevilla Sevilla Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,7,17]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24641"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.449"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature08309"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001092"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31824f5506"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60934-8"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0807650"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1010494"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2000.110973"},{"issue":"2","key":"e_1_2_7_11_1","first-page":"394A","article-title":"The pharmacokinetic behavior of pegylated (40 kD) interferon alfa\u20102a in chronic hepatitis C patients after multiple dosing","volume":"32","author":"Modi MW","year":"2000","journal-title":"Hepatology"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200010000-00010"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.43.11.5679-5684.2005"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.32150"},{"key":"e_1_2_7_15_1","doi-asserted-by":"crossref","first-page":"695","DOI":"10.3851\/IMP1821","article-title":"Impact of ribavirin on HCV replicon RNA decline during treatment with interferon\u2010\u03b1 and the protease inhibitors boceprevir or telaprevir","volume":"16","author":"Hofmann WP","year":"2011","journal-title":"Antivir Ther"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22448"},{"key":"e_1_2_7_17_1","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1177\/135965350400900405","article-title":"Viral dynamics and pharmacokinetics of peginterferon alpha\u20102a and peginterferon alpha\u20102b in naive patients with chronic hepatitis C: a randomized, controlled study","volume":"9","author":"Bruno R","year":"2004","journal-title":"Antivir Ther"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21136"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2006.00803.x"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.21227"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.20560"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2008.110"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2007.01.027"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn013"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22217"},{"key":"e_1_2_7_26_1","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1177\/135965350801300401","article-title":"Prediction of sustained virological response by ribavirin plasma concentration at week 4 of therapy in hepatitis C virus genotype 1 patients","volume":"13","author":"Maynard M","year":"2008","journal-title":"Antivir Ther"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2009.04065.x"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2010.01399.x"},{"key":"e_1_2_7_29_1","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1177\/135965350701200815","article-title":"Early monitoring of ribavirin serum concentration is not useful to optimize hepatitis C virus treatment in HIV\u2010coinfected patients","volume":"12","author":"Crespo M","year":"2007","journal-title":"Antivir Ther"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis449"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03705.x"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.04.013"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1086\/656235"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0018322"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.01.050"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1086\/605677"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8278(91)90084-O"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23624"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.1.124-129.2003"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21853"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0707882105"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23912"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.04.049"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-10-25"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2007.00860.x"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23130"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.08.051"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2009.08.036"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.03.039"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3283471d53"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.21583"},{"key":"e_1_2_7_52_1","first-page":"10","article-title":"Differences in virological response to peginterferon\u2010\u03b1 plus ribavirin in HIV\u20101 positive patients coinfected with HCV subtypes 1a or 1b","volume":"2012","author":"Rall\u00f3n NI","journal-title":"JAIDS"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.11.055"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvh.12128","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvh.12128","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.12128","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T08:15:10Z","timestamp":1696148110000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.12128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,17]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["10.1111\/jvh.12128"],"URL":"https:\/\/doi.org\/10.1111\/jvh.12128","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,17]]}}}